Lab21 hires cfo

Susan Lowther joins Cambridge, UK-based firm

Lab21, a Cambridge, UK-based specialist in personalised medicine, has hired Susan Lowther as chief financial officer.

Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.

Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’

You may also like

Research & Development

Lab21 sells South Carolina laboratory operations

Will continue to focus on diagnostic content opportunities within the US market
Finance

Lab21 acquires Myconostica

Expands growing proprietary diagnostic portfolio
Pharmaceutical
OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT begins full IVDR transition for CytoCell FISH probe portfolio

OGT has launched two IVDR-certified prenatal FISH probe kits as it begins transitioning its full CytoCell portfolio ahead of the EU’s 2028 Class C deadline
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Manufacturing
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction

The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
Research & Development
Digitalisation: more space for research and development in Salzburg, Austria

Digitalisation: more space for research and development in Salzburg, Austria

COPA-DATA is investing €15 million in the project, underlining its long-term commitment to Salzburg and Austria as a location for technology, research and innovation
Finance
Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

Ratio Therapeutics raises $70m to expand radiopharmaceutical manufacturing

The Series C financing will support clinical development of Ratio’s Ac-225 radiotherapeutic pipeline and expansion of its radiopharmaceutical manufacturing infrastructure
Subscribe now